Eucrisa (crisaborole) / Pfizer - LARVOL DELTA

Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Tanta University

New trial • Dermatology • Immunology • Vitiligo

Synergistic Effects of Activatable Photodynamic Therapy and Crisaborole for Psoriasis through Senolysis and Immunomodulation. (PubMed, J Med Chem) - "This "dual-target" approach demonstrated superior efficacy compared to monotherapies. Our work pioneers a "dual-target/modal" strategy and addresses both cellular senescence and inflammatory cascades in psoriasis, providing a novel strategic direction for psoriasis treatment optimization."

Journal • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis

Safety and tolerability of roflumilast cream from INTEGUMENT-1/2 trials of patients with atopic dermatitis and prior failure of topical treatments (CDA 2025) - P3 | "Patients aged ≥6 years with AD, Eczema Area and Severity Index ≥5, and Validated Investigator Global Assessment for AD (vIGA-AD) of Mild or Moderate were randomized 2:1 to once-daily roflumilast cream 0.15% or vehicle for 4 weeks. Safety and local tolerability were assessed through adverse events and investigator- and patient-rated local tolerability scales. Of 1137 patients in this pooled analysis (884 roflumilast, 453 vehicle), 60.8% reported prior TCS failure, 18.0% TCI failure, and 7.3% crisaborole failure."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pain

Efficacy and Safety of Phosphodiesterase-4 Inhibitors in Vitiligo: A Systematic Review (CDA 2025) - "Oral apremilast was most commonly used (110/114, 96.4%) followed by topical crisaborole (4/114, 3.5%). A MEDLINE, Cochrane, and Embase search was conducted under PRISMA guidelines using the following keywords and variations: “vitiligo” and “PDE4i”. The search yielded 11 studies with 114 participants with a mean age of 38.1 years (range: 16-71 years), consisting of 49% males. Treatments were categorized as PDE4i treatment with concomitant medications (85/114, 74.5%) or PDE4i monotherapy (29/114, 25.4%)."

Clinical • Review • Dermatology • Immunology • Vitiligo

New topical molecular targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis. (PubMed, Pediatr Allergy Immunol) - "Nine studies (reported in eight articles) involving 2182 patients were included, with 1469 children treated with Janus kinase inhibitors (ruxolitinib and delgocitinib) and phosphodiesterase-4 inhibitors (crisaborole, lotamilast, and difamilast)...New topical targeted therapies administered over 4 weeks are effective and safe for children with atopic dermatitis aged ≤18 years. Further studies are needed to establish their long-term safety and efficacy."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Pharmacokinetics, Bioequivalence, and Safety Studies of Crisaborole Ointment in Healthy Chinese Subjects. (PubMed, Clin Pharmacol Drug Dev) - "During the study, 5 subjects had 8 adverse events, and no serious adverse events were reported. In this study, the tested formulation of crisaborole ointment is bioequivalent to the reference formulation, and the safety is comparable."

Journal • PK/PD data

Effect of NB-UVB combined with Creborol ointment in the treatment of non-segmentary vitiligo in stable stage (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: The Fifth People Hospital of Chongqing; The Fifth People Hospital of Chongqing

New P4 trial • Dermatology • Immunology • Vitiligo

PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact. (PubMed, J Drugs Dermatol) - "Among available agents, roflumilast stands out for its high potency and selectivity, with a half-maximal inhibitory concentration of 0.7 nM compared to 140 nM for apremilast (200-fold less) and 750 nM for crisaborole (1071-fold less). 2025;24(6):631-633. doi:10.36849/JDD.9089."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation • Lichen Planus • Pediatrics • Psoriasis • Seborrheic Dermatitis • Vitiligo

Inhibition of Activated Coagulation Factor XII by the Phosphodiesterase-4 Inhibitor Roflumilast: In Vitro and In Silico Studies. (PubMed, Front Biosci (Landmark Ed)) - "Overall, roflumilast could be used as a lead compound for developing a novel multifunctional therapeutic drug used for the prevention of HAE or thrombotic disorders."

Journal • Preclinical • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Hereditary Angioedema • Inflammation • Thrombosis

Crisaborole in Hailey-Hailey Disease: A Case Report. (PubMed, J Dermatol) - No abstract available

Journal • Genetic Disorders

Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Wake Forest University Health Sciences | Active, not recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Racial and ethnic disparities in atopic dermatitis medication utilization (SID 2025) - "We examined disparities in the utilization of treatments for AD, specifically dupilumab, crisaborole, topical JAK inhibitors (TJAKIs), and topical calcineurin inhibitors (TCIs). These findings suggest significant disparities in AD treatment across demographic groups. Further investigation is needed to identify underlying factors and inform interventions to ensure equitable access to AD therapies."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Topical and oral phosphodiesterase-4 inhibitors for refractory seborrheic dermatitis: A systematic review (SID 2025) - "Topical crisaborole 2% (5.02%) and oral apremilast 30mg (0.47%) were also used. The use of PDE-4 inhibitors represents a significant advancement in the management of SD, especially in patients needing long-term management, with these results highlighting their efficacy and tolerability. As more clinical data become available, PDE-4 inhibitors are likely to become a cornerstone in the treatment of SD."

Review • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Pruritus • Seborrheic Dermatitis • IL10

Clinical efficacy of the combination treatment of psoriasis vulgaris with crisaborole ointment in comparison with calcipotriene ointment (SID 2025) - "05), and the overall therapeutic efficacy of the treatment group (with an effective cure rate of 38.46%) was better than that of the control group (28.91%) (P<0.05); the overall incidence of adverse reactions in the treatment group was lower than that of the control group (P<0.05). The results of the study showed that the efficacy of Crisaborole Ointment combined with Captopanol Ointment in the treatment of psoriasis vulgaris was remarkable, which could effectively alleviate the clinical symptoms and improve the skin condition with good therapeutic effect and safety, and provided a new and effective choice for the treatment of psoriasis."

Clinical • Dermatology • Immunology • Psoriasis

PDE4 inhibitors in psoriasis therapy: current insights and future directions. (PubMed, Inflammopharmacology) - "The review gathered detailed information about clinical research and pharmaceutical operations of PDE4 inhibitors, specifically for apremilast, roflumilast, and crisaborole. This review also analyzes experimental PDE4 inhibitors alongside the advantages that appear when combining these drugs with biologics or phototherapy, together with methotrexate...New drug dosage methods connected to personalized treatment plans have the potential to raise patient care effectiveness. Researchers need to study ways to improve PDE4 inhibitor formulations, along with developing new combination therapy approaches to enhance sustained psoriasis disease treatment."

Journal • Review • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • TNFA

IL-4, IL-13, TNF-α and IFN-γ Downregulate CLDN8 Expression Through Activating JAK Signaling Pathway in HaCaT Cells. (PubMed, Clin Cosmet Investig Dermatol) - "CLDN8 mRNA expression is decreased in AD lesions and MC903-induced AD-like mouse model. Downregulation of CLDN8 mRNA expression is alleviated after dupilumab or crisaborole treatment...Skin tissues might not express CLDN8 protein. AD-related cytokines including IL-4, IL-13, TNF-α and IFN-γ could downregulate CLDN8 mRNA expression through activating JAK."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Oncology • CLDN8 • IFNG • IL13 • IL4 • TNFA

Topical Crisaborole for the Treatment of Recalcitrant Palmoplantar Pustulosis: A Case Series. (PubMed, Dermatol Ther (Heidelb)) - "The positive response of topical crisaborole observed in our cases also echoes the efficacy of apremilast, a systemic phosphodiesterase 4 (PDE4) inhibitor which successfully treated PPP in other reports, highlighting the potential role of PDE4 in the pathophysiology of PPP. Further studies are needed for a more comprehensive evaluation."

Journal • Immunology • Psoriasis

Effectiveness and safety of topical phosphodiesterase 4 inhibitors in children with mild-to-moderate atopic dermatitis: A systematic review and meta-analysis. (PubMed, J Int Med Res) - "Currently, crisaborole appears to be the optimal choice for balancing safety and efficacy. As research in this area is still in its early stages, further high-quality trials are essential for establishing standards of clinical care.INPLASY registration number: INPLASY202520121."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Drug development in dermatology: challenges in treating young patients. (PubMed, Expert Opin Pharmacother) - "For crisaborole for atopic dermatitis, the FDA accepted pivotal trials involving patients 2-79 years; the EMA accepted this as part of its PIP...Companies must possess a deep understanding of the clinical landscape, considerable patience, and sometimes seek external experts' support. A gap has become wider between US and EU, with the EU increasingly falling behind in drug development."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • Psoriasis

Study on the microscopic characteristics of skin blood vessels in inflammatory skin diseases and the efficacy and safety of abrocitinib tablets combined with Crisborole ointment in the treatment of moderate to severe atopic dermatitis (ChiCTR) - P=N/A | N=300 | Completed | Sponsor: China-Japan Friendship Hospital; The Beijing Qingnang Huimin Medical Research Institute Co., Ltd.

New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Pfizer introduces two novel therapies to treat patients across the atopic dermatitis disease spectrum (The Star) - "PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia. Cibinqo is a once-daily oral pill indicated for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis..."

Launch non-US • Atopic Dermatitis

PAD: Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (clinicaltrials.gov) - P4 | N=72 | Terminated | Sponsor: Boston University | N=118 ➔ 72

Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Molecular mechanism of crisaborole combined with erythromycin against methicillin-resistant Staphylococcus aureus in vivo and in vitro. (PubMed, Front Microbiol) - "Here, we identified (AN2728) produced a significant synergistic bactericidal effect with erythromycin, cefuroxime and rifampicin against different bacterial strains of Staphylococcus aureus (S. Moreover, in a mouse skin infection model of MRSA, the combination of AN2728 and erythromycin showed remarkable treatment benefits, as shown by significantly reduced bacterial loading (p < 0.05), pathological lesions of the skin and an obvious anti-inflammatory effect (p < 0.05). To our knowledge, this study is the first to establish that AN2728 can cooperate with antibiotics such as erythromycin to completely kill MRSA and that AN2728 can be used to extend the usage life of different antibiotics to address the inevitability of severe MRSA infection."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease

Rural-urban disparities in the use of FDA-approved steroid-sparing topical medications for inflammatory dermatologic conditions: A DataDerm study (AAD 2025) - " Compared to rural patients, urban patients were more likely to be prescribed 3 of 6 topicals queried: crisaborole (OR 1.46, p<0.001), roflumilast (OR 11603130, p<0.001), and tacrolimus (OR 1.57, p<0.001). While odds ratios for pimecrolimus, tapinarof, and tazarotene also exceeded 1.0, no statistically significant differences were observed for these medications. There is an evident disparity in prescribing patterns for steroid-sparing topical medications between urban and rural populations, with the former being less likely to incur steroid-related adverse effects such as dermal atrophy. This could be attributable to differences in the concentration of dermatologists between these areas (4), with rural patients encountering significantly more obstacles in accessing dermatologic care."

Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis

Comparative evaluation of the efficacy and safety of crisaborole ointment versus tacrolimus ointment for the topical treatment of atopic dermatitis-A randomized controlled trial (AAD 2025) - "Localized burning sensation was seen in both groups, with tacrolimus showing more incidence of the adverse event. Conclusion The study demonstrated that crisaborole and tacrolimus ointment have comparable efficacy in treating atopic dermatitis; however, crisaborole has a superior safety profile."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus